CA1228295A - Trousse ou dispositif et methode pour l'administration de gangliosides et de leurs derives par inhalation et compose pharmaceutique utilisable a cette fin - Google Patents

Trousse ou dispositif et methode pour l'administration de gangliosides et de leurs derives par inhalation et compose pharmaceutique utilisable a cette fin

Info

Publication number: CA1228295A
Authority: CA; Canada
Prior art keywords: kit; ganglioside; pharmaceutical composition; pharmaceutically; acid
Prior art date: 1984-10-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000466641A

Other languages

English (en)

Inventor

Francesco Della Valle

Aurelio Romeo

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Fidia SpA

Original Assignee

Fidia SpA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-10-30

Filing date

1984-10-30

Publication date

1987-10-20

1984-10-30 Application filed by Fidia SpA filed Critical Fidia SpA

1984-10-30 Priority to CA000466641A priority Critical patent/CA1228295A/fr

1987-10-20 Application granted granted Critical

1987-10-20 Publication of CA1228295A publication Critical patent/CA1228295A/fr

Status Expired legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 27
150000002270 gangliosides Chemical class 0.000 title abstract description 62
238000000034 method Methods 0.000 title description 22
239000000203 mixture Substances 0.000 claims abstract description 52
150000002148 esters Chemical group 0.000 claims abstract description 44
-1 ganglioside compound Chemical class 0.000 claims abstract description 41
150000003839 salts Chemical class 0.000 claims abstract description 23
150000001720 carbohydrates Chemical class 0.000 claims abstract description 22
239000002253 acid Substances 0.000 claims abstract description 17
SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims abstract description 15
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 15
235000014633 carbohydrates Nutrition 0.000 claims abstract description 14
239000007921 spray Substances 0.000 claims abstract description 14
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 11
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 10
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims abstract description 9
CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims abstract description 9
229940106189 ceramide Drugs 0.000 claims abstract description 9
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims abstract description 9
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims abstract description 9
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 8
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims abstract description 5
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims abstract description 5
239000008103 glucose Substances 0.000 claims abstract description 5
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims abstract description 4
SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 claims abstract description 4
FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 claims abstract description 4
FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 claims abstract description 4
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims abstract description 4
239000003085 diluting agent Substances 0.000 claims abstract description 4
230000008760 nerve sprouting Effects 0.000 claims abstract description 4
239000003937 drug carrier Substances 0.000 claims abstract description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract 2
239000000843 powder Substances 0.000 claims description 9
239000000725 suspension Substances 0.000 claims description 6
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical group CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 4
229940124630 bronchodilator Drugs 0.000 claims description 4
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 1
229960001317 isoprenaline Drugs 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 24
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
238000002627 tracheal intubation Methods 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
239000007864 aqueous solution Substances 0.000 description 10
238000007918 intramuscular administration Methods 0.000 description 10
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 9
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
239000003153 chemical reaction reagent Substances 0.000 description 8
239000000243 solution Substances 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 7
229920001467 poly(styrenesulfonates) Polymers 0.000 description 7
241000700159 Rattus Species 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
230000009102 absorption Effects 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 6
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 6
125000005629 sialic acid group Chemical group 0.000 description 6
239000007787 solid Substances 0.000 description 6
238000011282 treatment Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 5
235000019404 dichlorodifluoromethane Nutrition 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
WMYNMYVRWWCRPS-UHFFFAOYSA-N ethynoxyethane Chemical group CCOC#C WMYNMYVRWWCRPS-UHFFFAOYSA-N 0.000 description 5
239000008101 lactose Substances 0.000 description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
241000283690 Bos taurus Species 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
239000002775 capsule Substances 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
229930182830 galactose Natural products 0.000 description 4
239000012528 membrane Substances 0.000 description 4
210000005036 nerve Anatomy 0.000 description 4
159000000000 sodium salts Chemical class 0.000 description 4
241000894007 species Species 0.000 description 4
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical group CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 4
239000000126 substance Substances 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
ZNPNOVHKCAAQCG-UHFFFAOYSA-N 2-chloro-1-methylpyridin-1-ium Chemical class C[N+]1=CC=CC=C1Cl ZNPNOVHKCAAQCG-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
210000005013 brain tissue Anatomy 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
210000000944 nerve tissue Anatomy 0.000 description 3
108091006112 ATPases Proteins 0.000 description 2
102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
244000186140 Asperula odorata Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
235000008526 Galium odoratum Nutrition 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
150000007942 carboxylates Chemical group 0.000 description 2
208000015114 central nervous system disease Diseases 0.000 description 2
230000003412 degenerative effect Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000003456 ion exchange resin Substances 0.000 description 2
229920003303 ion-exchange polymer Polymers 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
229950006780 n-acetylglucosamine Drugs 0.000 description 2
239000007922 nasal spray Substances 0.000 description 2
229940097496 nasal spray Drugs 0.000 description 2
238000002663 nebulization Methods 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
230000002232 neuromuscular Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
230000007170 pathology Effects 0.000 description 2
230000000149 penetrating effect Effects 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical group C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 2
239000000700 radioactive tracer Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000011084 recovery Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000008279 sol Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
210000003437 trachea Anatomy 0.000 description 2
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
WCVOGSZTONGSQY-UHFFFAOYSA-N 2,4,6-trichloroanisole Chemical compound COC1=C(Cl)C=C(Cl)C=C1Cl WCVOGSZTONGSQY-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
XSFWDHONRBZVEJ-UHFFFAOYSA-N 7-[3-[[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino]propyl]-1,3-dimethylpurine-2,6-dione;hydron;chloride Chemical compound Cl.C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 XSFWDHONRBZVEJ-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
208000010346 Sphingolipidoses Diseases 0.000 description 1
201000001307 Sphingolipidosis Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
125000001549 ceramide group Chemical group 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000013329 compounding Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
150000002339 glycosphingolipids Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
238000007273 lactonization reaction Methods 0.000 description 1
235000020778 linoleic acid Nutrition 0.000 description 1
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
DUZPCMXUYQIWCZ-UHFFFAOYSA-N n'-(3-phenylpropyl)methanediimine Chemical compound N=C=NCCCC1=CC=CC=C1 DUZPCMXUYQIWCZ-UHFFFAOYSA-N 0.000 description 1
LUKVNUBQLMJEOI-UHFFFAOYSA-N n-benzyl-n'-propan-2-ylmethanediimine Chemical compound CC(C)N=C=NCC1=CC=CC=C1 LUKVNUBQLMJEOI-UHFFFAOYSA-N 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
239000011356 non-aqueous organic solvent Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
150000002888 oleic acid derivatives Chemical class 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
208000027232 peripheral nervous system disease Diseases 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000003507 refrigerant Substances 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
150000003408 sphingolipids Chemical class 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical group CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

CA000466641A 1984-10-30 1984-10-30 Trousse ou dispositif et methode pour l'administration de gangliosides et de leurs derives par inhalation et compose pharmaceutique utilisable a cette fin Expired CA1228295A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000466641A CA1228295A (fr)	1984-10-30	1984-10-30	Trousse ou dispositif et methode pour l'administration de gangliosides et de leurs derives par inhalation et compose pharmaceutique utilisable a cette fin

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000466641A CA1228295A (fr)	1984-10-30	1984-10-30	Trousse ou dispositif et methode pour l'administration de gangliosides et de leurs derives par inhalation et compose pharmaceutique utilisable a cette fin

Publications (1)

Publication Number	Publication Date
CA1228295A true CA1228295A (fr)	1987-10-20

Family

ID=4129035

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000466641A Expired CA1228295A (fr)	1984-10-30	1984-10-30	Trousse ou dispositif et methode pour l'administration de gangliosides et de leurs derives par inhalation et compose pharmaceutique utilisable a cette fin

Country Status (1)

Country	Link
CA (1)	CA1228295A (fr)

1984
- 1984-10-30 CA CA000466641A patent/CA1228295A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2004-10-30	MKEX	Expiry

Publication	Publication Date	Title
US4639437A (en)	1987-01-27	Kit or device and method for administering gangliosides and derivatives thereof by inhalation and pharmaceutical compositions suitable therefor
CA1230596A (fr)	1987-12-22	Methode de preparation de derives de gangliosides et utilisation dans des composes pharmaceutiques
DE69232101T2 (de)	2002-06-20	Lipid-derivate von phosphonsäuren für liposomale inkorporation und verwendungsverfahren
DE68928920T2 (de)	1999-07-22	Fettsäure-arzneimittel-konjugat zur verabreichung von arzneimitteln durch die blut-gehirn-schranke
DE69319912T2 (de)	1999-04-15	Triantennar cluster glykoside, ihre herstellung und verwendung
DE69024862T2 (de)	1996-09-05	Modifiziertes, biologisch aktives Protein
US20040092455A1 (en)	2004-05-13	Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
JPH02124830A (ja)	1990-05-14	ガングリオシドーリポソームビヒクル中の刺激因子の制御放出製剤
JPS6030651B2 (ja)	1985-07-17	経鼻投与用インスリ製剤
EP1704864B9 (fr)	2012-09-19	Préparation pharmaceutique injectable constituée d'un agent cytostatique et d'une fonction maléinimide liés par un espaceur.
EP0279887B1 (fr)	1995-02-01	Agents pharmaceutiques dirigés par la carnitine et leur utilisation pour la fabrication d'un médicament pour le traitement d'une maladie musculaire
CN112574098B (zh)	2022-06-07	一种酰胺化合物及其制备方法和用途
US5202313A (en)	1993-04-13	Bilobalide derivatives, their applications and formulations containing them
US5183807A (en)	1993-02-02	Use of monosialoganglioside gm, to prevent the development of tolerance to the analgesic effect of morphine and related drugs
US4742081A (en)	1988-05-03	Carnitine coupled pharmaceutical agents
DE2166355C2 (de)	1983-12-08	Verwendung von d,1-Sobrerol bei der Balsamtherapie der Atemwege
US5314906A (en)	1994-05-24	Derivatives of physostigmine, their use and pharmaceutical formulations containing them
JPH0217559B2 (fr)	1990-04-20
US20040176281A1 (en)	2004-09-09	Delivery systems
KR910009687A (ko)	1991-06-28	Nmda-저해 제약성분
JPS61502192A (ja)	1986-10-02	経口活性ヘパリン多重体
PH26117A (en)	1992-02-24	Therapeutic use of the isopropyl ester derivative of monosialoganglioside in nervous pathologies with an inflammatory component
CN115960013A (zh)	2023-04-14	一类具有双子表面活性剂结构特征的季铵甲酸盐化合物、超分子自组装及应用
DE69328585T2 (de)	2001-01-04	Neue Alkaloidderivate, ihre Verwendung und diese enthaltende pharmazeutische Formulierungen
EP0061711B1 (fr)	1984-06-13	10B-Carboxyaminoboranes, leur procédé de préparation et leur utilisation comme médicament pour capturer des neutrons